Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Recruiting

Phase 1

Phase 2

Zongertinib & TrastuzumabBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Sponsor:

Boehringer Ingelheim

Code:

NCT06324357

Conditions

Metastatic Breast Cancer

Metastatic Gastric Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

Esophageal Adenocarcinoma

Colorectal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zongertinib

Trastuzumab deruxtecan

Trastuzumab emtansine

Trastuzumab

Capecitabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-25. This information was provided to ClinicalTrials.gov by Boehringer Ingelheim on 2026-06-24.